ArticleJournal of thoracic disease2026
Is the consolidation-to-tumor ratio an independent prognostic factor in clinical T1 stage lung adenocarcinoma radiologically manifesting as a subsolid nodule?-a retrospective cohort study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies indicate that preoperative radiological features, particularly the consolidation-to-tumor ratio (CTR), are associated with prognosis in stage IA lung adenocarcinoma. However, the prognostic value of different CTR thresholds remains controversial in lung adenocarcinoma manifesting as subsolid nodules (SSNs), and whether CTR is an independent prognostic factor has not yet been clarified. Our study aimed to investigate prognostic differences among T1 stage SSN lung adenocarcinoma patients with varying CTR thresholds, maximum solid component diameters (MCDs), and maximum tumor diameters (MTDs). We also sought to explore the independent prognostic value of CTR in this group. Methods: This retrospective study included patients with cT1 stage SSN lung adenocarcinoma who underwent radical resection at The First Affiliated Hospital of Shandong First Medical University between December 2017 and December 2021. The Kaplan-Meier was used to estimate overall survival (OS) and recurrence-free survival (RFS), with the log-rank test comparing survival curves between groups. Firth's penalized Cox regression analysis was employed to identify independent prognostic factors for T1 stage SSN lung adenocarcinoma. Results: A total of 509 SSNs from 493 patients were analyzed [230 pure ground-glass nodules (pGGNs) and 279 partly solid nodules (PSNs)], with a median follow-up duration of 50.3 months (range, 3.5-86.0 months). Kaplan-Meier analysis showed that the 5-year OS rate for T1 stage SSN lung adenocarcinoma patients was 98.6% [95% confidence interval (CI): 97.4-99.9%], with a 5-year RFS rate of 98.3% (95% CI: 97.0-99.7%). Among SSN lung adenocarcinomas, only the difference in OS between the 0< CTR ≤0.25 and 0.25< CTR <1 groups was statistically significant. Regarding RFS, statistically significant differences were observed between different CTR threshold groups, MCD groups classified according to the 8 Conclusions: CTR >0.25, MCD >10 mm, and MTD >20 mm are associated with a poorer prognosis in T1 stage SSN lung adenocarcinoma. However, neither CTR, MCD, nor MTD is not an independent prognostic factor for the group; preoperative CEA levels represent more stable and independent prognostic predictors than CTR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.